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Soluble mesothelin-related peptide (SMRP) is a promising biomarker for malignant
pleural mesothelioma (MPM), but several confounding factors can reduce SMRP-based
test’s accuracy. The identification of these confounders could improve the diagnostic
performance of SMRP. In this study, we evaluated the sequence of 1,000 base pairs
encompassing the minimal promoter region of the MSLN gene to identify expression
quantitative trait loci (eQTL) that can affect SMRP. We assessed the association between
four MSLN promoter variants and SMRP levels in a cohort of 72 MPM and 677 non-
MPM subjects, and we carried out in vitro assays to investigate their functional role.
Our results show that rs2235503 is an eQTL for MSLN associated with increased
levels of SMRP in non-MPM subjects. Furthermore, we show that this polymorphic
site affects the accuracy of SMRP, highlighting the importance of evaluating the
individual’s genetic background and giving novel insights to refine SMRP specificity as a
diagnostic biomarker.
Keywords: soluble mesothelin-related peptide, malignant pleural mesothelioma, diagnostic biomarkers, single
nucleotide polymorphisms, fluorescent reporter assay, eQTL
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a highly aggressive and rare cancer of the pleura
triggered by exposure to asbestos and associated with a poor prognosis (Bianchi et al., 2017).
The long latency between the exposure to asbestos and the onset of the disease, the unspecific
symptoms at the presentation, and the lack of accurate and non-invasive diagnostic tools make
the diagnosis quite challenging (Rusch et al., 2012; Bianco et al., 2018). Thus, MPM is often
diagnosed at advanced stages, thereby further reducing the limited therapeutic options available
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and resulting in poor prognostic outcomes. The identification
of accurate diagnostic biomarkers, or the optimization of those
identified so far, could help to overcome this problem (Sun
et al., 2017). To date, one of the most promising biomarkers
for the diagnosis of MPM is “soluble mesothelin-related peptide”
(SMRP), which is released in the extracellular environment
following the proteolytic cleavage of mesothelin (a membrane
protein encoded by the MSLN gene) (Sapede et al., 2008). The
plasmatic concentration of SMRP is easily measurable from
blood samples, and it is usually higher in MPM than in non-
MPM subjects (either healthy or affected by other respiratory
conditions), allowing fair discrimination between these two
groups (Gao et al., 2019; Gillezeau et al., 2019). Despite these
promising features, several confounding factors can reduce the
accuracy of SMRP as a diagnostic biomarker, thereby preventing
its employment in the clinical practice. While many studies
extensively documented the impact of age, body mass index,
glomerular filtration rate (Casjens et al., 2017), and tumor
histology on SMRP (Scherpereel et al., 2006), none of them
explored the role of the genetic background. However, we believe
that the genetic background could play a prominent role in
this context. An increasing number of studies, by showing the
importance of genetic variations in altering the concentration and
the accuracy of several biomarkers, strongly support this idea
(Cramer et al., 2003; Gudmundsson et al., 2010; Enroth et al.,
2014; Ruggiero et al., 2015; Wang et al., 2018). Furthermore, we
showed for the first time that single nucleotide polymorphisms
(SNPs) located within the 3′-UTR of the MSLN gene could
affect the SMRP levels through a miRNA-mediated mechanism
(Garritano et al., 2014). Recently, we reported similar results
for other variants lying within the MSLN promoter (De Santi
et al., 2017). Based on these observations, we hypothesized that
expression quantitative trait loci (eQTL) for MSLN could affect
the plasmatic concentration and the accuracy of SMRP. Thus,
we assessed the association between SNPs located within the
promoter region of MSLN and the plasmatic levels of SMRP
in a cohort of 72 MPM and 677 non-MPM subjects. We
carried out in vitro assays to investigate the functional role
of these SNPs, and highlighted the relationship between the
transcriptional rate of MSLN gene and serum concentrations of
SMRP. Our results show that evaluating the individual’s genotype
to establish personalized cutoff values can increase the diagnostic
accuracy of SMRP, thereby helping to promote its translation into
clinical practice.
MATERIALS AND METHODS
Selection of the SNPs
Following the hypothesis that the transcriptional rate of the
MSLN gene could affect the plasmatic concentration of SMRP,
we extracted a window of 1,000 base pairs upstream of the
transcription starting site (TSS), encompassing the minimal
promoter region, using the UCSC genome browser1. Within
this sequence, we selected those SNPs showing a minor allele
1https://genome.ucsc.edu/
frequency (MAF) >0.05 and a significant association with MSLN
mRNA levels in lung tissues (according to the GTEx Portal
V6p2). This selection led to the identification of four SNPs
worth of further investigations: rs3764247 A > C, rs3764246
A > G, rs2235503 C > A and rs2235504 A > G (Supplementary
Table 1). According to 1,000 Genomes3, their combination elicits
four haplotypes (Table 1), accounting for almost the totality
(98.5%) of the genetic variability of the promoter region within
Caucasians, and Tuscans.
Genotyping, Haplotype Reconstruction,
SMRP Measurements and Association
Study
Detailed information about the studied population, DNA
extraction, genotyping, and measurement of SMRP levels can
be found elsewhere (De Santi et al., 2017). Briefly, we analyzed
a total of 677 non-MPM and 72 MPM volunteers. Among the
677 non-MPM, 371 were healthy people, while 306 were patients
affected by benign respiratory diseases (BRD). All the subjects
were recruited at the University Hospital of Pisa as part of
an occupational surveillance program on workers previously
exposed to asbestos, as described by Garritano et al. (2014). Blood
and serum samples were obtained by venipuncture and store at
−80◦C. To measure the plasmatic concentration of the SMRP,
we employed the Mesomark enzyme-linked immunosorbent
assay (Fujirebio Diagnostics, Japan) following the manufacturer’s
instructions. We carried out DNA extraction and genotyping
using the EuroGOLD Blood DNA Mini Kit (EuroClone, Pero,
Italy) and the KASPar PCR SNP genotyping system (LGC
Genomics Ltd., Teìddington, Middlesex, United Kingdom),
respectively. For this study, we reconstructed the individual
haplotypes and diplotypes using PHASE 2.1.1 (Stephens et al.,
2001; Stephens and Scheet, 2005) and stratified our cohort
according to health status and diplotypes. To precisely assess the
effect of each haplotype, we restricted the association study to
carriers of the haplotype #1 (e.g., H1H2, H1H3, and H1H4), using
the H1H1 homozygotes as reference. The number of subjects
excluded from the analysis was minimal (19 non-MPM and 6
MPM) and did not hamper the statistical power of the study.
Cell Lines
For the functional study, we employed a non-malignant SV40-
immortalized epithelial cell line (MeT-5A) and an epithelioid
malignant mesothelioma cell line (Mero-14). MeT-5A were
purchased from ATCC (American Type Culture Collection, CRL-
9444) and cultured in Medium-199 (Gibco, Life Technologies,
Monza, Italy) supplemented with 10% fetal bovine serum (FBS),
1% penicillin/streptomycin, 3 nM epidermal growth factor
(EGF), 400 nM hydrocortisone and 870 nM insulin. Mero-14
were kindly donated by Istituto tumori of Genova (National
Research Council, Genova, Italy) and cultured in Dulbecco’s
modified Eagle’s medium (DMEM; EuroClone, Pero, Italy)
supplemented with 10% FBS and 1% penicillin/streptomycin.
Both cell lines were maintained at 37◦C and 5% CO2.
2https://gtexportal.org/
3https://www.internationalgenome.org/1000-genomes-browsers/
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Construction of Plasmids
In the first part of this work, we aimed to evaluate the role of the
four haplotypes herein identified in affecting the activity of the
MSLN promoter. Thus, we constructed four vectors to employ in
the functional study. Each of these vectors harbored one of the
haplotypic variants immediately upstream of a green fluorescent
protein (GFP) coding sequence. The same vectors also harbored
a red fluorescent protein (RFP) coding sequence controlled by
the constitutive eukaryotic promoter EF1 (Figure 1A). For the
cloning procedure, we employed the CloneEZ PCR cloning kit
(GenScript, Piscataway, United States). We used the HR220PA-
1 vector (System Bioscience, Palo Alto, United States) linearized
with BstBI (New England BioLabs, Ipswich, United States) and
DNA fragments representing the four haplotypic variants of
the MSLN promoter. Each of these fragments was obtained by
PCR using as a template the genomic DNA of four subjects
homozygote for one of the four selected haplotypes (now on
abbreviated as H1–H4 when referring to the human genomic
DNA, or HAP1–HAP4 when referring to the cloned fragment).
The resulting vectors were named HR_HAP1 to HR_HAP4.
In the second part of this work, we aimed to ascertain the
individual role of each of the selected SNPs. To this end, we
created three additional vectors, each harboring the uncommon
variant of only one of the four SNPs. These vectors were
named HR_246, HR_503, and HR_504 and were obtained from
HR_HAP1 by site-directed mutagenesis using the Quick Change
Lightning Site-Directed Mutagenesis Kit (Agilent). Consistently
with the terminology employed in this second phase of the
study, since the HR_HAP4 differs from the HR_HAP1 only for
the rs3764247, bearing the C-allele instead of the A-allele, we
renamed it “HR_247.” Figure 1A shows the details of the changes
introduced by the site-directed mutagenesis to generate these
additional vectors.
Fluorescent Reporter Assay
To evaluate the effect of the selected haplotypes and SNPs on the
transcriptional activity of the MSLN promoter, we employed a
fluorescent reporter assay. To this end, 2 × 105 cells/ml were
electroporated with 10 µg of plasmid DNA, seeded into a six-
well plate, and incubated at 37◦C and 5% CO2 for 72 h. After the
incubation, we harvested the cells by trypsinization and measured
the GFP/RFP fluorescence intensity using the BD FACSJazz
System (BD Biosciences, Franklin Lakes, United States). We used
the untreated sample to set the RFP intensity threshold for the
selection of efficiently transfected cells (Figure 1B). Similarly,
we used cells transfected with the “empty” HR220PA-1 vector
(expressing the RFP but not the GFP reporter gene) to establish
the average background signal detected by the FITC/GFP channel
(Figure 1C). These two steps allowed us to restrict the statistical
analysis only to the cells that were efficiently transfected, and that
showed a GFP signal above the average background (Figure 1D;
P3). All the electroporation steps were carried out using the
Neon Transfection System (Thermo Fisher Scientific, Monza,
Italy), and the following parameters: 1,230 V, 30 ms, 2 pulses for
MeT-5A and 1,130 V, 30 ms, 2 pulses for Mero-14.
Statistical Analyses
For the statistical analyses, we employed GraphPad PRISM 7.0
software. We carried out the analysis of variance (ANOVA) for
the association study and the multifactor ANOVA (mANOVA)
for the functional studies, both followed by Dunnett’s multiple
comparison test. To evaluate the diagnostic performance of
SMRP along with the optimal cutoff values, we calculated
the receiver operating characteristic (ROC) curves employing
the same software.
RESULTS
Haplotype #2 and Haplotype #3 Are
Associated With SMRP Levels in vivo
Among the non-MPM volunteers, we found a statistically
significant difference between the plasmatic levels of SMRP in
heterozygotes H1H2, H1H3, and H1H4 compared with those
TABLE 1 | Number of individuals stratified according to their health status and genotype at single allele/diplotype level. “MPM” represents patients affected by malignant
pleural mesothelioma, while “non-MPM” identifies subjects exposed to asbestos (healthy or affected by benign respiratory diseases). Table also shows the variants (rs)
that characterize each haplotype.
Haplotypes distribution and sequences
Distribution among studied population
Single Alleles Non-MPM MPM rs3764247 rs3764246 rs2235503 rs2235504
Haplotype 1 (H1) 1047 105 A A C A
Haplotype 2 (H2) 209 24 C G A G
Haplotype 3 (H3) 109 13 A G C G
Haplotype 4 (H4) 47 4 C A C A
Diplotypes Non-MPM MPM
H1H1 389 39
H1H2 152 14
H1H3 78 11
H1H4 39 2
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FIGURE 1 | Construction of the plasmids and cells selection. (A) scheme of the vectors harboring the four haplotypic variants of MSLN promoter (HR_HAP1 to
HR_HAP4) upstream of a GFP reporter gene employed in the functional study. The same vectors also harbor an internal control represented by an RFP reporter
gene under the control of the elongation factor 1 (EF1) constitutive promoter. HR_HAP1 has been used as a template for a site-directed mutagenesis procedure, to
obtain the vectors HR_246/503/504 that have been employed to assess the effect of the single SNPs in altering the GFP expression. The SNPs variants are circled
in red. (B–D) Graphs showing the fluorescence intensity, at single cell level, measured using FITC/GFP (GFP fluorescence) and mCherry/PE-594 (RFP fluorescence)
filters with BD FACSJazz System. (B) Untransfected cells (P1) have been used as a control to establish the RFP intensity threshold for the successfully transfected
cells. (C) Cells successfully transfected (P2) with the empty vector HR220PA-1, expressing only the RFP reporter gene, have been used to determine the average
GFP background level. (D) The statistical analysis has been restricted to successfully transfected cells that showed a GFP signal above the average GFP
background (P3) (HR_HAP1 is reported as an example).
of the reference group H1H1 (p-value ANOVA < 10−5). The
Dunnett’s post-test showed a statistically significant difference
between carriers of haplotype #2 or haplotype #3, but not
haplotype #4, and the reference H1H1 (p-value < 10−5 and
0.0047, respectively) (Figure 2A). On average, carriers of
haplotype #2 showed the highest SMRP level (average± standard
error: 1.30 ± 0.046 nM) followed by carriers of haplotype #3, #1,
and #4 (0.98± 0.060 nM, 0.80± 0.022 nM, and 0.78± 0.047 nm,
respectively). We did not observe any significant difference
within the group of MPM patients (Figure 2B).
In vitro Studies Confirm the Functional
Role of Haplotype #2 and Identify
rs2235503 C > A as the Most Likely
Causative SNP
To evaluate whether the haplotype #2 and #3 could enhance
the activity of the MSLN promoter, we carried out in vitro
experiments using a fluorescence reporter assay. We transfected
MeT-5A and Mero-14 cells with HR vectors carrying the GFP
reporter gene under the control of the different haplotypic
variants of MSLN promoter, named HR_HAP1, HR_HAP2,
HR_HAP3, and HR_HAP4 (Figure 1A). Results showed a
statistically significant difference among haplotypes but not
between cell lines (mANOVA p-value = 0.0016 and 0.67). When
compared to cells transfected with HR_HAP1, cells transfected
with HR_HAP2 showed a 1.41-fold increased RFU (±0.267;
p-value = 6 × 10−4). HR_HAP3 conferred a slight increased
expression, but not statistically significant (1.07 ± 0.131;
p-value = 0.45). HR_HAP4 showed a promoter activity similar
to HR_HAP1 (0.97 ± 0.05; p-value = 0.98) (Figure 2C).
Since haplotype #2 carries the uncommon variants of the four
SNPs, we investigated the functional role of each of them, by
employing four more constructs: HR_247, HR_246, HR_503, and
HR_504 (Figure 1A). Each of these vectors bore the uncommon
variant of rs3764247, rs3764246, rs2235503, or rs2235504, thus
differing from HR_HAP1 only for one SNP. Again, mANOVA
showed a statistically significant difference among genotypes
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FIGURE 2 | Results of the association and functional studies. (A,B) Bar charts showing the association between the genetic variants of MSLN promoter and the
levels of soluble mesothelin-related peptide (SMRP) measured in blood samples from non-MPM subjects (A) and from patients affected by pleural mesothelioma
(MPM) (B) stratified according to their individual diplotypes. The Bar charts show the concentration of SMRP expressed in nM, along with the standard error of the
mean (SEM) (∗p < 0.05, one-way ANOVA and Dunnett’s post-test). (C,D) bar charts showing the relative fluorescence units (RFU), along with SEM, of cells 72 h after
being electroporated with vectors harboring the four haplotypic variants of MSLN promoter (C) or the rare variant for each of the considered SNPs (circled) (D)
upstream of a GFP reporter. Since no statistically significant difference between the RFU of the two cell lines emerged from the mANOVA, the data from MeT-5A and
Mero-14 have been combined (∗p < 0.05, one-way ANOVA and Dunnett’s post-test).
but not between cell lines (p-value < 10−5 and 0.15). When
compared with HR_HAP1, only cells transfected with HR_503
showed a significant RFU increase (fold change 1.35 ± 0.164;
p-value < 10−5) (Figure 2D).
Rs2235503 C > A Significantly Affects the
Performance of SMRP as Diagnostic
Biomarker for MPM
Since the results indicated that the uncommon variant
A-rs2235503 caused an increase in MSLN expression and
SMRP levels in non-MPM subjects, we sought to determine
whether this effect could significantly affect the accuracy of
SMRP as a diagnostic biomarker for MPM. To verify this
aspect, we stratified our cohort in two subgroups, the former
containing the carriers of A-rs2235503 (rs2235503_C/A + A/A)
and the latter containing all the other subjects (rs2235503_C/C).
We then used the SMRP levels to calculate the “ROC” curve
for each of the two subgroups. Results suggested a strong
influence of the genotype on the performance of SMRP. In
fact, the ROC curve for the C/A + A/A group resulted in an
area under the curve (AUC) of only 0.798 ± 0.055 compared
with an AUC of 0.915 ± 0.018 for the C/C group (Figure 3A).
Interestingly, the AUC for the C/C group was also higher than
that for the overall population (0.877 ± 0.019). Moreover, the
Youden index pointed at an optimal cut-off value of 1.118
(sensitivity = 84.31, specificity = 82.86) for the C/C group, and
3.092 (sensitivity = 52.58, specificity = 96.69) for the C/A + A/A
group. The optimal cut-off value for the overall population
was 1.28, with a sensitivity of 77.78 and a specificity of 79.91.
Notably, using a cut-off of 1.28 nM, the specificity for the C/C
group raised to 88.71, but the sensitivity dropped to 76.47.
Similarly, the specificity for the C/A + A/A group raised to
55.80, but the sensitivity dropped to 80.95. Supplementary
Tables 2–4 report the complete list of the possible cut-off
values along with the associated sensitivity and specificity for
each group. These results were not surprising as the difference
in the average SMRP concentration between non-MPM and
MPM subjects, although still significant (p-value < 0.0001),
dropped from 2.734 ± 0.174 nM for the C/C group to only
1.706 ± 0.388 nM for the A/A group (Figure 3B). Intriguingly,
data from GTEx Portal (V8) showed a similar trend for the
tagging SNP rs12597489 C > T, in linkage disequilibrium (LD)
with rs2235503 (r2 = 0.8 according to HaploReg v4.1), suggesting
a strong relationship between the mRNA levels of MSLN and
the serum concentration of SMRP (Figure 3C). To explore the
potential relationship between the rs2235503 and the prognosis
of MPM patients, we carried out a survival analysis. The results
showed a lack of association between this SNP and the overall
survival (p-value = 0.66). The multivariate analysis performed
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FIGURE 3 | Effect of rs2235503 on SMRP and MSLN. (A) ROC curves showing the performance of SMRP as diagnostic biomarker for MPM in the subset of
individuals carrying the common variant of the rs2235503 C > A (rs2235503_C/C) and in the subset of subjects carrying at least one rare variant of the same SNP
(rs2235503 C/A + A/A). (B) Comparison between the plasmatic concentrations of SMRP in non-MPM subjects stratified based on their rs2235503 alleles, and in
MPM patients. The dots represent the log10 [SMRP] (nM) of each subject. The red lines represent the median of the log10 [SMRP] (n.s.p > 0.05; ∗p < 0.05;
∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.) (C) Violin plot showing the normalized levels of MSLN mRNA in lung samples from 515 subjects stratified based on their
rs12597489 C > T alleles, according to the GTEx Portal V8. Given the good linkage disequilibrium between the rs2235503 C > A and the rs12597489 C > T
(r2 = 0.8), we considered this latter as a “tagging SNP” for rs2235503. According to GTEx, the minor allele of this SNP is associated with MSLN mRNA with a
p-value of 1 × 10-49 and a normalized effect size (NES) of 0.88.
to evaluate the prognostic significance of rs2235503, SMRP,
and histology led to similar results, with none of these factors
being significantly associated with prognosis (Supplementary
Figures 1A,B).
DISCUSSION
Soluble mesothelin-related peptide is one of the most promising
biomarkers for MPM, but its sensitivity and specificity are
suboptimal for use in the clinical practice (Scherpereel et al.,
2006; Casjens et al., 2017). Our previous data showed that SNPs
within regulatory regions of the MSLN gene were associated
with SMRP levels, raising the question of whether the evaluation
of these variants could improve the performance of SMRP in
the diagnosis of MPM (Garritano et al., 2014; De Santi et al.,
2017). Herein, we explored the possibility of exploiting eQTL for
MSLN to increase the diagnostic accuracy of SMRP. Firstly, we
carried out an association study in a cohort of 677 non-MPM
subjects and 72 MPM patients. We found that two haplotypes
(#2 and #3) of the minimal promoter region of the MSLN
gene were associated with increased serum levels of SMRP in
non-MPM subjects. In agreement with our previous studies,
we did not observe any association in the cohort of MPM
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patients (Garritano et al., 2014; De Santi et al., 2017). While
we cannot rule out that the lack of association observed in
MPM patients could be ascribed to a limited statistical power
(n = 72), Goricar et al. (2020) recently reported similar results,
showing that the minor allele of the rs1057147 was associated
with increased SMRP levels in non-MPM (n = 782) but not
in MPM subjects (n = 154). Together, these observations seem
to corroborate the hypothesis that genotype has only a limited
effect on SMRP levels in the malignant context, probably due to
the major role played by other cancer-related factors in altering
SMRP concentration. However, more studies on other cohorts
of MPM patients are warranted for better exploring this effect
among affected people (Pass et al., 2008). Nonetheless, the in vitro
assays confirmed the functional role of haplotype #2, able to
increase the expression of a reporter gene in a chimerized vector
of about 42%. Moreover, cells transfected with a vector harboring
the A-rs2235503 showed increased promoter activity of a similar
extent, compared to C-rs2235503. This result straightened the
role of haplotype #2 and pinpointed rs2235503 as the SNP
responsible for the enhancement of MSLN gene expression.
Since SMRP derives from the proteolytic cleavage of mesothelin
(Sapede et al., 2008), it is conceivable that its plasmatic levels
can be influenced by factors such as the eQTL for MSLN. Our
work supports the rationale that the polymorphism rs2235503
is among these factors. Unfortunately, we could not perform
any measurement of mRNA MSLN expression on the cohort of
volunteers recruited in this study, however, indirectly, also the
data from 525 lung samples within GTEx biobank confirmed
a relationship between the genotype and the extent of MSLN
gene transcription. Conversely, our in vitro studies ruled out the
possibility of a functional role for the SNPs that characterize
the haplotype #3 (i.e., rs3764246 and rs2235504). Thus, likely,
the association observed in vivo should be ascribed to other
SNPs in LD with haplotype #3 but residing outside the 1,000-
bps promoter region herein considered. Since the results from
other groups suggest the possibility of a prognostic significance of
SMRP-affecting SNPs (Dipalma et al., 2011; Goricar et al., 2020),
we tested whether genotype and SMRP levels could be predictive
of a worse prognosis in our cohort. Our observations seem to
rule out this hypothesis. Given the flaw association between
SNP and SMRP among patients, and the lack of association
between SMRP and overall survival, it is not surprising that
there is a lack of significant relationship between SNP and
patients’ survival in our cohort. However, given the limited
number of MPM patients recruited in the present study, this
result should be carefully evaluated and more work involving
additional cohorts is needed to elucidate the prognostic role of
the rs2235503. Then, we assessed whether the performance of
SMRP could be improved when taking into account the subjects’
genetic background, in agreement with previous findings for
other biomarkers (Cramer et al., 2003; Gudmundsson et al.,
2010; Enroth et al., 2014; Ruggiero et al., 2015; Wang et al.,
2018). Notably, we found that the AUC for individuals carrying
the rs2235503-C/C genotype was higher (0.915) than that of
carriers of the A-allele (0.798) and higher as compared to the
whole population (0.877). Moreover, the Youden index pointed
at significantly different cut-off values according to the rs2235503
genotypes, suggesting that the stratification of subjects based on
this SNP could improve the accuracy of SMRP. In conclusion, our
work shows that rs2235503 affects MSLN gene transcription and
represents an eQTL for SMRP levels. Moreover, we highlighted
for the first time that the rs2235503 can affect the diagnostic
performance of SMRP, reinforcing the importance of considering
the individual genetic background to improve the accuracy of
cancer biomarkers (Cramer et al., 2003; Gudmundsson et al.,
2010; Enroth et al., 2014; Wang et al., 2018). Therefore, it is
conceivable that the characterization of further eQTL could help
to translate SMRP into the clinical practice and improve the
efficiency of this biomarker.
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